Health & Fitness
Health and Fitness
Health and Fitness
Thu, December 1, 2011
Wed, November 30, 2011
Transcept Pharmaceuticals to Host Conference Call to Discuss Purdue's Exercise of Option to Commercialize Intermezzo in the Uni
Transcept Pharmaceuticals to Host Conference Call to Discuss Purdue's Exercise of... -- POINT RICHMOND, Calif., Nov. 30, 2011 /PRNewswire/ --
Transcept Pharmaceuticals to Host Conference Call to Discuss Purdue's Exercise of Option to Commercialize Intermezzo? in the United States
Call Scheduled for Thursday, December 1, 2011 at 8:30 a.m. ET
POINT RICHMOND, Calif., Nov. 30, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]) announced today that it will host a conference call to discuss the exercise by Purdue of its option to commercialize Intermezzo® (zolpidem tartrate) sublingual tablet C-IV in the United States.
Conference Call Information
Date: Thursday, December 1, 2011
Time: 8:30 a.m. ET
Dial-in (U.S.): 877-638-4558
Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at [ www.transcept.com ]. A replay of the call will be available on the website shortly after the conclusion of the call until December 31, 2011.
A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business December 9, 2011. The replay telephone numbers are 855-859-2056 (U.S.) and 404-537-3406 (International), replay passcode: 32092646.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Transcept and Purdue have entered into a collaboration agreement for the development and commercialization of Intermezzo in the United States.
Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, to determine its effectiveness and safety when used as augmentation treatment in patients with obsessive-compulsive disorder who have not adequately responded to first-line pharmacotherapy. For further information, please visit the Transcept website at [ www.transcept.com ].
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]
SOURCE Transcept Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.transcept.com ]
